Instructions for Amlodipine Aspartate Tablets
Release time:
2020-07-31
Approval Date: October 23, 2006
First Amendment Date: June 20, 2010
Second Amendment Date: May 05, 2015
Amlodipine Aspartate Tablets Instruction
Aspartic acid Amlodipine Tablets
Please read the instruction carefully and use
[Drug Name]
generic name under the guidance of a doctor: amlodipine aspartate tablets
trade name: liside
English name: Aspartic acid Amlodipine Tablets
Chinese pinyin: Men dong an suan an lu di ping plan-
[ingredients] the main ingredient of this product is L-amlodipine aspartate
chemical name: 2-1 [2-aminoethoxy] methyl] -4-1 (2-chlorophenyl) -1,4-dihydrogen -6-methyl pyridine -3,5-3-ethyl -5-methyl ester L-a-aspartic acid salt.
Chemical Structural Formula:
Molecular Formula: C20H25CIN205 C4H7N04
Molecular Weight: 541.99
[Character] This product is white or white-like sheet
[Indications] It can be used alone or in combination with other antihypertensive drugs to treat hypertension
[Specification] 5mg (based on amlodipine)
[Usage and Dosage] Usually the initial dose is 5mg (one sheet) once a day, but the elderly, frail, liver damage patients and patients with other antihypertensive drugs, the initial dose can be 2.5mg (half a tablet), once a day. Dosage adjustment should be based on the clinical response of the individual patient, the maximum dose can be increased to 10mg (two tablets), once a day. This product is combined with thiazide diuretics, beta blockers and angiotensin converting enzyme inhibitors without dose adjustment.
[Adverse Reactions] The more common adverse reactions are headache, edema, fatigue, insomnia, nausea, abdominal pain, flushing, palpitations and dizziness. Less common adverse reactions are angina, hypotension, bradycardia, orthostatic hypotension, pruritus, rash, dyspnea, weakness, muscle cramps, and dyspepsia. This product is similar to other calcium antagonists, there are few reports of adverse reactions of myocardial infarction and chest pain, and these adverse reactions can not be clearly distinguished from the patient's own underlying disease; no abnormal laboratory parameters related to this product have been found.
[Contraindications] Patients allergic to dihydropyridine calcium antagonists are contraindicated.
[Precautions]
L. Patients with impaired liver function: As with all other calcium blockers, the half-life of this product is prolonged when liver function is impaired, but the corresponding recommended dose has not yet been determined. Therefore, this product should be used with great care in this case.
2. Patients with renal failure: This product is widely metabolized into inactive metabolites, and only 10% of the drugs are excreted in the original form through urine. Therefore, the change of blood drug concentration is not related to the degree of renal damage. Patients with renal damage can use normal doses. This product is not dialysis.
3. This product, such as other calcium ion blockers, can rarely have gingival hyperplasia, which mostly occurs during 1-9 months of treatment, but symptoms and hyperplasia can be improved l-21 weeks after drug withdrawal.
4. There is no need to stop the drug before surgery, but the anesthesiologist must know to use this drug for treatment.
. The following conditions are prohibited:
① Severe hypotension:
② Aortic stenosis.
[Use for pregnant and lactating women] The safety of this product for pregnant and lactating women has not been established. In animal experiments, rats were given 10 mg/kg of this product. In addition to delayed delivery and prolonged labor, intrauterine death increased 5 times and the number of littermates decreased by 50%. Therefore, this product can only be used when there is no other safer alternative drug and the disease itself is more dangerous to mother and child. There are no reports on whether this product is discharged into milk.
[Children's medication] There is no information on this product for children.
[Elderly Medication] The peak time of blood drug concentration of this product is similar in elderly and young patients. The area under the curve (AUC) of elderly patients is increased, the elimination half-life is prolonged, and the clearance rate is decreased. It has been reported that older patients were as well tolerated as younger patients when receiving similar doses of amlodipine. Therefore, the elderly patients can use the normal dose, but it is advisable to start with a smaller dose, and then gradually increase the appropriate.
[Drug Interactions]
(1) Narcotics: Inhalation of hydrocarbon drugs with this product can cause hypotension.
(2) non-steroidal anti-inflammatory drugs, especially indomethacin: with this product can weaken the hypotensive effect, may be related to the inhibition of prostaglandin synthesis and (or) cause water, sodium retention.
(3) beta blockers: well tolerated with this product, but can cause excessive hypotension, rare cases can increase the possibility of congestive heart failure.
(4) Estrogen: Use with this product can increase fluid retention and increase blood pressure.
(5) Sulfopyrone (sulfinpyrazone): combined with this product can increase the protein binding rate of amlodipine and change the blood drug concentration.
(6) Lithium preparations: When used with this product, it can cause neurotoxicity, such as nausea, vomiting, diarrhea, ataxia, tremor and (or) numbness, and should be used with caution.
(7) Sympathomimetic amines may attenuate the antihypertensive effect of this product.
[Drug Overdose] Existing data suggest that severe overdose can lead to excessive dilatation of peripheral blood vessels, followed by significant and lasting systemic hypotension, bradycardia, rare II or III degree atrioventricular block, and cardiac arrest in a few patients. The former should be given intravenous dopamine, norepinephrine treatment. The latter should be given atropine, isopropyl kidney, calcium chloride treatment, if there are indications should be placed pacemaker.
[Pharmacological Toxicology]
Pharmacological Effects
This product is a calcium ion influx blocker (I. e. calcium channel blocker or calcium ion antagonist), which can selectively inhibit calcium ion from flowing into vascular smooth muscle and myocardial cells across the membrane, especially for vascular smooth muscle. This product directly dilates vascular smooth muscle, dilates peripheral arterioles, reduces peripheral resistance (afterload), and significantly dilates coronary arteries. This product has a negative inotropic effect in vivo, but has no effect on the sinoatrial node and atrioventricular node.
Toxicological Study
Acute Toxicity in Mice: The LD 50 of L-aspartate amlodipine bulk drug administered by gavage is 80.2 mg/kg(95% confidence limit is 71.3-90.2 mg/kg); The LD 50 for intraperitoneal injection is 62.1 mg/kg(95% confidence limit is 55.0-70.1 mg/kg).
Genotoxicity: Mutagenicity test results indicate no drug-related gene or chromosome level mutagenicity.
Reproductive toxicity: General reproductive toxicity test, oral administration of amlodipine 10 mg/kg/day (based on body surface area, about 8 times the maximum recommended human dose of lOmg) to rats has no damage to fertility. Oral administration of 10 mg/kg of amlodipine (about 8 times and 23 times the maximum recommended human dose of 10mg in terms of body surface area, respectively) to pregnant rats and rabbits during organogenesis had no teratogenic effect on embryos. However, oral administration of amlodipine 10 mg/kg 14 days before mating and pregnancy in rats significantly reduced the number of littermates (about 50%), increased intrauterine mortality (about 5 times), and prolonged pregnancy and labor. Adequate and well-controlled trials have not been conducted in pregnant women, so pregnant women should only take this product during pregnancy when their potential benefits are large and potentially dangerous to the fetus.
It is not clear whether this product is excreted in human milk. In view of the lack of information in this regard, it is recommended to stop using it during lactation.
Carcinogenicity: Amlodipine is carcinogenic in rats and mice for two years. Mixed food doses of 0.5,1.25, and 2.5 mg/kg/day are non-carcinogenic. The highest dose (calculated by body surface area, the mouse dose is equivalent to the maximum recommended clinical dose of 10mg, while the rat dose is twice) is close to the maximum tolerance of mice.
[Pharmacokinetics] It is reported in the literature that this product is well absorbed orally and is not affected by food intake. The plasma protein binding rate is about 97.5, the blood drug concentration reaches the peak value 6-12 hours after single administration, the absolute bioavailability is about 64-80%, the apparent distribution volume is about 21L/kg, the final elimination half-life is about 35-50 hours, once a day, after 7-8 days of continuous administration, blood drug concentration reached steady state. This product is widely metabolized by the liver into inactive metabolites, 10% of which are excreted as original drugs and 60% as metabolites through urine.
【Storage】 Shaded, sealed and stored in a dry place..
【Packing】 Aluminum-plastic plate packaging, each small carton containing seven or fourteen pieces.
[Validity] 24 months.
[Implementation Standard] WS-(X-101)-2005Z
[Approval Document No.] Guoyao Zhun Zi H20020487
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No. 58 Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province
Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax
:
More information
Jiang Xiaomeng Yunnan Jianfeng Lectures on Party Lessons
In order to implement the requirements of the higher-level party committee secretary to give in-depth party lectures in enterprises, on July 4, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, gave a special lecture on "two studies and one doing" for party members at Yunnan Jianfeng Cement Company. In the lecture, Jiang Xiaomeng started from the background, overall requirements, learning and education content, and main measures of the "two studies and one doing" activities. He hoped that all party members and cadres would understand "awe, gratitude, humility, and decent", and put forward "What should the current enterprise do" and "How should the enterprise go in the future" and other issues. Jiang Xiaomeng analyzed the future development trend of cement and pharmaceutical industries in detail, emphasized the importance of seizing opportunities, and pointed out that with the homogenization of cement industry becoming more and more serious, if we want to take the road of differentiated brand development, the core of competition is to strengthen self management and maximize the cost, so as to improve the competitive advantage. As far as Yunnan Jianfeng is concerned, it is necessary to continuously improve the level of process technology management and increase the hourly output by increasing inspection efforts. Starting from strengthening the control of raw material procurement, the quality and price should be controlled. By strengthening sales management, vigorously develop direct agents, and strive to maximize the profit per ton; By strengthening equipment maintenance, reduce equipment accidents and further reduce the consumption of machine materials; Make good use of people, while constantly tapping talents and cultivating new people, we will gradually control the total number of workers and improve labor productivity. According to the current situation and the company's development strategy, what should the party members of the peak do? Jiang Xiaomeng asked all the party members and cadres of Yunnan peak to play a good vanguard and exemplary role and take the lead in learning new knowledge, new technology and new experience.
2020
07-30
Yunnan Peak Starts Secondary Security Standardization Creation
On June 19, Yunnan Jianfeng cement company held a mobilization meeting to further implement the requirements of the State Council, Yunnan Province, Pu'er City and Simao District Safety Supervision Bureau on carrying out safety production standardization work, and deploy the secondary safety standardization work. At the meeting, Liu Shenghua, deputy general manager of Yunnan Jianfeng, read out the requirements and work arrangements for creating a secondary enterprise for safety production standardization. The representative of Yunnan superstar Safety Technology Service Co., Ltd., the evaluation unit of safety production standardization, explained in detail the relevant knowledge of safety production standardization consultation and evaluation for the participants, and explained the requirements, standards and other elements of safety production standardization work. Zhou Jiping, general manager of Yunnan Jianfeng, mobilized the establishment of secondary safety production standardization at the meeting, requiring all workshops and departments to prepare and report the data before the end of October, and both software and hardware meet the acceptance conditions, so as to complete the bid creation work by the end of the year. Through the mobilization meeting, the responsible persons of Yunnan Jianfeng and superstar companies and relevant personnel had in-depth exchanges, further unified their thinking, and improved Yunnan Jianfeng employees' understanding of safety production standardization. Everyone recognizes that carrying out safety production standardization work is not only to implement the spirit of a series of documents of the party and the country, but also a mandatory requirement of the government for enterprises, and it is also the need for the sustainable and healthy development of enterprises themselves. Through the development of safety production standardization, enterprises can be promoted to establish and improve the safety production responsibility system, improve the safety production management system, standardize the production operation behavior, investigate and control the hidden dangers of accidents, effectively control the sources of danger, make the production equipment and facilities meet the safety standards, and continuously improve
2020
07-31
Yunnan Peak Starts Secondary Security Standardization Creation
On June 19, Yunnan Jianfeng cement company held a mobilization meeting to further implement the requirements of the State Council, Yunnan Province, Pu'er City and Simao District Safety Supervision Bureau on carrying out safety production standardization work, and deploy the secondary safety standardization work. At the meeting, Liu Shenghua, deputy general manager of Yunnan Jianfeng, read out the requirements and work arrangements for creating a secondary enterprise for safety production standardization. The representative of Yunnan superstar Safety Technology Service Co., Ltd., the evaluation unit of safety production standardization, explained in detail the relevant knowledge of safety production standardization consultation and evaluation for the participants, and explained the requirements, standards and other elements of safety production standardization work. Zhou Jiping, general manager of Yunnan Jianfeng, mobilized the establishment of secondary safety production standardization at the meeting, requiring all workshops and departments to prepare and report the data before the end of October, and both software and hardware meet the acceptance conditions, so as to complete the bid creation work by the end of the year. Through the mobilization meeting, the responsible persons of Yunnan Jianfeng and superstar companies and relevant personnel had in-depth exchanges, further unified their thinking, and improved Yunnan Jianfeng employees' understanding of safety production standardization. Everyone recognizes that carrying out safety production standardization work is not only to implement the spirit of a series of documents of the party and the country, but also a mandatory requirement of the government for enterprises, and it is also the need for the sustainable and healthy development of enterprises themselves. Through the development of safety production standardization, enterprises can be promoted to establish and improve the safety production responsibility system, improve the safety production management system, standardize the production operation behavior, investigate and control the hidden dangers of accidents, effectively control the sources of danger, make the production equipment and facilities meet the safety standards, and continuously improve
2020
07-31
Yunnan Peak Starts Secondary Security Standardization Creation
On June 19, Yunnan Jianfeng cement company held a mobilization meeting to further implement the requirements of the State Council, Yunnan Province, Pu'er City and Simao District Safety Supervision Bureau on carrying out safety production standardization work, and deploy the secondary safety standardization work. At the meeting, Liu Shenghua, deputy general manager of Yunnan Jianfeng, read out the requirements and work arrangements for creating a secondary enterprise for safety production standardization. The representative of Yunnan superstar Safety Technology Service Co., Ltd., the evaluation unit of safety production standardization, explained in detail the relevant knowledge of safety production standardization consultation and evaluation for the participants, and explained the requirements, standards and other elements of safety production standardization work. Zhou Jiping, general manager of Yunnan Jianfeng, mobilized the establishment of secondary safety production standardization at the meeting, requiring all workshops and departments to prepare and report the data before the end of October, and both software and hardware meet the acceptance conditions, so as to complete the bid creation work by the end of the year. Through the mobilization meeting, the responsible persons of Yunnan Jianfeng and superstar companies and relevant personnel had in-depth exchanges, further unified their thinking, and improved Yunnan Jianfeng employees' understanding of safety production standardization. Everyone recognizes that carrying out safety production standardization work is not only to implement the spirit of a series of documents of the party and the country, but also a mandatory requirement of the government for enterprises, and it is also the need for the sustainable and healthy development of enterprises themselves. Through the development of safety production standardization, enterprises can be promoted to establish and improve the safety production responsibility system, improve the safety production management system, standardize the production operation behavior, investigate and control the hidden dangers of accidents, effectively control the sources of danger, make the production equipment and facilities meet the safety standards, and continuously improve
2020
07-30
The Company shall organize special operation safety management training
What kind of management process is needed for the special operation permit? How to manage the ticket of the special operation permit? What are the contents of the eight kinds of special operations?... On June 17, the safety committee of the group company organized a special lecture on safety production to conduct systematic and comprehensive training on the safety management knowledge of special operations. The trainer invited for this training is Ge Zhengliang, head of EHS (Environmental Environment, Health Health, Safety) of Zhejiang Prodbang Pharmaceutical Co., Ltd. He has many years of experience in enterprise safety production management and is also a well-known safety management expert in Jinhua region. He has participated in the enterprise safety and environmental protection inspection organized by Jinhua Safety Supervision Bureau for many times and has a certain understanding of the situation of major enterprises in the peak. In this lecture, Ge Zhengliang divided into four parts: division of special operation license scope, special operation license management process, special operation license ticket management, and eight major types of special operation contents. Combined with relevant laws and regulations and his own practical experience in safety production management, Ge Zhengliang explained in simple terms eight special operation situations such as hot work, hoisting, high place, temporary power consumption, open circuit, blind plate plugging, restricted space, etc, standardize the licensed business division, approval department, the places to be paid attention to in the approval management of each type of operation, the responsibilities of the relevant approval department, the matters needing attention in on-site operation, the approval process, ticket management and other knowledge, and make a detailed description of the relevant special operation contents according to the working characteristics of peak subordinate enterprises. In addition, he also shared the experience of special operation safety management of Plo Pharmaceutical.
2020
07-31
Yunnan Jianfeng won the honor of "key leading enterprise in Pu'er City"
Recently, Yunnan Jianfeng Cement Company was awarded the honorary title of "2016 Pu'er Key Leading Enterprise" by the Pu'er Municipal Party Committee and Municipal Government. In recent years, according to the requirements of the group company's "three reductions and three improvements", Yunnan Jianfeng has focused on internal management and external market expansion, tried every means to reduce costs in production, timely controlled market trends in sales, and constantly refreshed various business indicators. While striving to create its own brand value, Yunnan Jianfeng always regards giving back to the society and serving local development as its own responsibility and obligation. Since the establishment of the company, Yunnan Jianfeng has actively responded to the government's call to support the construction of poor border areas and provide free cement to some poor people. Support the education construction in border areas and donate funds for students in need. At the same time, it has paid various taxes and fees on time in accordance with the law and has become a major profit and tax producer in Pu'er City for years. It has gradually grown from a new cement enterprise in Pu'er area to a leading enterprise in the cement industry. The honor of "key leading enterprises in Pu'er City in 2016" is the affirmation and recognition of Yunnan Jianfeng's work over the past few years by the local government and society. During the "Thirteenth Five-Year Plan" period, southwestern Yunnan is about to usher in an explosive stage of development. The construction of international railway projects, the construction of border expressway projects, the construction of airport projects and the construction of people's livelihood projects will all start this year. The acquisition of the honorary title of "Key Leading Enterprise in Pu'er City in 2016" will also provide strong support for Yunnan Jianfeng to strive for the right to supply these projects. (Li Yun)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page